Justin Klee (L) and Josh Cohen, Amylyx co-CEOs
Ahead of FDA committee to discuss new ALS drug, the jury remains out on how much benefit is enough for approval
Next week, an FDA advisory committee will face an all-too familiar question: Should a drug for a fatal, neurodegenerative disease be approved despite less than …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
